Literature DB >> 8076257

Epidemiology of systemic sclerosis.

T A Medsger1.   

Abstract

Systemic sclerosis is a family of disorders most appropriately considered in the category of the connective tissue diseases. Two major forms are recognized (diffuse cutaneous and limited cutaneous involvement subtypes), each with distinctive clinical and serologic findings as well as natural history. Scleroderma is characterized epidemiologically by several distinctive features. From a demographic viewpoint, the disease spares children and its incidence increases steadily with age among adults. If occurs much more frequently in women, especially during the child-bearing years, and most often and most severely in young black women, though there is no overall prominent racial predilection. The annual incidence approaches 20 per million population, and may be considerably underestimated. Both incidence and mortality have increased during the past several decades, but these changes are most likely a result of improved case detection rather than a true increase in incidence. Prevalence studies have not been undertaken, but 500 per million population may be a reasonable estimate. Family and genetic studies suggest a weak genetic predisposition, but several strong HLA associations with scleroderma-specific serum autoantibodies are evident. Certain environmental agents may be implicated in pathogenesis of scleroderma and closely related systemic illnesses associated with cutaneous fibrosis. The widespread pathologic process in systemic sclerosis leads to vascular insufficiency and fibrosis, which diminishes the reserve function of many organ systems. The result is considerable disability, especially affecting hand function, and a significant reduction in life span, with an overall 10-year survival from first physician diagnosis of under 70%. Further epidemiologic studies should take full advantage of established and newly proposed subsets of patients with homogeneous clinical, laboratory, serologic, and natural history features. The environment-host interactions noted here must be fully explored, especially in early untreated disease, where primary rather than secondary mechanisms are most likely to be operative.

Entities:  

Mesh:

Year:  1994        PMID: 8076257     DOI: 10.1016/s0738-081x(94)90323-9

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  7 in total

1.  Videofluorography swallow study of patients with systemic sclerosis.

Authors:  S Russo; G Lo Re; M Galia; A Reginelli; V Lo Greco; T D'Agostino; G La Tona; F Coppolino; R Grassi; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2009-06-26       Impact factor: 3.469

2.  Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.

Authors:  B Marasini; M Gagetta; V Rossi; P Ferrari
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  Comparison of Level of Fatigue and Disease Correlates in Patients With Rheumatoid Arthritis and Systemic Sclerosis.

Authors:  Kevser Gök; Kemal Erol; Gizem Cengiz; Salih Özgöçmen
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

Review 4.  Reproductive Issues and Pregnancy Implications in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Francesca Crisafulli; Liala Moschetti; Paolo Semeraro; Ana-Rita Cunha; Agna Neto; Andrea Lojacono; Francesca Ramazzotto; Cristina Zanardini; Sonia Zatti; Paolo Airò; Angela Tincani; Franco Franceschini; Laura Andreoli
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-18       Impact factor: 8.667

5.  Response of T-cell subpopulations to superantigen and recall antigen stimulation in systemic sclerosis.

Authors:  Sajad Ahmad Dar; Sambit Nath Bhattacharya; Shukla Das; Vishnampettai Ganapathysubramanian Ramachandran; Basu Dev Banerjee; Prateek Arora
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

6.  Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma.

Authors:  Agostino Di Ciaula; Michele Covelli; Massimo Berardino; David Q H Wang; Giovanni Lapadula; Giuseppe Palasciano; Piero Portincasa
Journal:  BMC Gastroenterol       Date:  2008-02-27       Impact factor: 3.067

Review 7.  Pharmacology and rationale for imatinib in the treatment of scleroderma.

Authors:  Pia Moinzadeh; Nicolas Hunzelmann; Thomas Krieg
Journal:  J Exp Pharmacol       Date:  2013-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.